Do GLP-1 pills work? Pills vs. injections for weight loss

GLP-1 medications come in pill form as well as the injections you may already be familiar with. The US Food and Drug Administration (FDA) has approved them for both weight loss and type 2 diabetes, with several options on the market. 

So do GLP-1 pills work as well as injections? Nearly. Neither quite matches the average weight loss of a weekly injection, but both come close. For anyone who’d rather skip the needle, the pills are a genuine option.

Yes, GLP-1 pills work for weight loss. In clinical trials, the Wegovy pill (semaglutide) produced an average of 13.6% body weight loss over 64 weeks, and Foundayo (orforglipron) produced up to 11.2% over 72 weeks.

To put that in perspective, someone starting at 220 pounds might lose ~24 pounds with Foundayo, or ~30 pounds with the Wegovy pill.

Both pills work the same way as GLP-1 injections. They mimic glucagon-like peptide-1 (GLP-1), a hormone your body naturally releases after eating. GLP-1 slows digestion, signals fullness to your brain, and helps regulate blood sugar, so you eat less and feel full sooner.

Injectable Wegovy and Zepbound (tirzepatide) still come out ahead on average, but for people who prefer not to inject, the pill results are substantial.

Get started

As of publication, four GLP-1 pills are currently FDA-approved in the US: the Wegovy pill and Foundayo for weight loss, and the Ozempic pill and Rybelsus for type 2 diabetes.

Wegovy pill

The Wegovy pill contains the same active ingredient as injectable Wegovy and Ozempic: semaglutide.

For adults, it’s approved for adults with obesity or with excess weight and a related health condition, alongside a reduced-calorie diet and increased physical activity. It’s also approved for cardiovascular risk reduction.

There are four strengths available: 1.5 mg, 4 mg, 9 mg, and 25 mg, with only the highest dose proven as effective for weight loss. Dosing starts low to help minimize side effects and increases gradually, a titration process common to GLP-1s generally, though the specific strengths and timeline vary by drug.

Semaglutide is a peptide, which can be difficult to take by mouth. That’s because digestive enzymes in your gut can break it down, and it doesn’t readily cross the gut lining (a necessary step to reach the bloodstream). 

To get around those barriers, the Wegovy pill pairs semaglutide with an absorption enhancer called salcaprozate sodium, or SNAC. Think of SNAC as a chaperone: It temporarily reduces the acidity around the tablet, protecting semaglutide from breakdown long enough for your body to absorb it intact.

Because that absorption is so delicate, the Wegovy pill comes with strict timing rules. It should be taken:

• First thing in the morning, on a completely empty stomach

• With no more than 4 oz of water

• At least 30 minutes before eating, drinking anything else, or taking other medications

In trials, patients on the 25 mg dose lost an average of 13.6% of their body weight over 64 weeks.

Foundayo (orforglipron)

Foundayo is approved for adults with obesity, or adults carrying excess weight plus at least one weight-related health condition. Like the Wegovy pill, it’s indicated alongside a reduced-calorie diet and increased physical activity.

The tablet comes in six strengths — 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg — and like other GLP-1s, dosing is increased step-by-step over time.

Foundayo contains orforglipron, a small-molecule compound rather than a peptide. That makes it more resistant to digestive breakdown, so it doesn't need a fasting protocol. You can take it any time of day, with or without food.

Results-wise, people taking orforglipron lost an average of 11.2% of their body weight over 72 weeks in clinical trials.

Ozempic pill and Rybelsus (semaglutide)

The first GLP-1 pill to hit the US market was Rybelsus, back in 2019. As of May 2026, though, Rybelsus is being phased out and transitioned to the Ozempic pill. 

Both are oral versions of semaglutide that are approved for type 2 diabetes and cardiovascular risk reduction. The main difference is that the Ozempic pill is a reformulated tablet available in 1.5 mg, 4 mg, and 9 mg strengths. That being said, the inventory of the original Rybelsus doses (3 mg, 7 mg, and 14 mg) will still remain until depleted.

Like the Wegovy pill, both rely on the same SNAC absorption enhancer — just at lower doses suited to blood sugar management rather than weight loss.

The Ozempic pill and Rybelsus aren't approved for weight loss, so this hasn't been the focus during studies, though a diabetes trial tracked it as a secondary measure: patients on a 14 mg semaglutide dose lost an average of 2.3 kg (~5 pounds) more than placebo over 26 weeks. 

How closely a GLP-1 pill's results match an injection's depends on which drugs you're comparing. The maintenance dose of the Wegovy pill (25 mg) comes close to the typical maintenance dose (2.4 mg) of the Wegovy injection. Meanwhile, Foundayo falls further behind Zepbound'sstronger results.

The table below shows average weight loss and timeframes for each GLP-1 pill and injection covered in this article. 

The Wegovy pill and injectable Wegovy at its 2.4 mg dose are only about 1–2 percentage points apart (13.6% vs. 15.6%), though that difference widens to roughly 5 percentage points at the 7.2 mg dose of the injection (13.6% vs. 18.7%). For some people, the convenience of a daily pill may well outweigh that difference.

Being an injection doesn’t automatically mean greater weight loss, though. Saxenda (liraglutide), an older, once-daily GLP-1 injection, produced only about 8% weight loss over 56 weeks in clinical trials — lower than the averages reported in separate trials of the Wegovy pill and Foundayo.  The newer drugs have simply moved past it.

Of everything covered here, Zepbound produces the greatest average weight loss — up to 20.9%%. That's because tirzepatide, its active ingredient, targets two appetite-related hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), whereas the other GLP-1s currently available only target one. 

Side effects are broadly similar for GLP-1 pills and injections. Nausea, vomiting, and diarrhea are most common early in treatment or after a dose increase, and they tend to ease once you reach maintenance. One exception is that injections carry a risk of injection site reactions, like redness, swelling, or irritation where the needle goes in, while pills don't.

How much you pay for a GLP-1 pill depends heavily on your insurance (if any), preferred pharmacy, and other factors. 

Without coverage, list prices are high, but cash-pay prices through telehealth programs are much lower. On Ro, the two weight loss pills range from $149 to $299* per month, depending on the specific drug and dose.

Here are the cash-pay prices* for the Wegovy pill and Foundayo if prescribed on Ro: 

The Ozempic pill and Rybelsus list prices can run close to $1,000 per month without insurance.

*Terms and conditions may apply to certain doses. Prices reflect Ro's current pricing and cover only the medication. Ro Body membership is a separate charge. Prices can change, and insurance may bring any of these down to a copay if your plan covers the medication.

Yes, Ozempic now comes in pill form, but not for weight loss. For years, Ozempic was exclusively a weekly injection for type 2 diabetes and cardiovascular risk, often prescribed off-label for weight loss. 

In May 2026, Novo Nordisk rebranded its oral semaglutide tablet (Rybelsus) as the Ozempic pill, so Ozempic is now sold as both a pen and a pill. Older Rybelsus-branded tablets may still be on pharmacy shelves while stock lasts.

Like the injection, the Ozempic pill is approved for type 2 diabetes and cardiovascular risk, not weight loss. If weight loss is your goal, the two pill options are the Wegovy pill and Foundayo.

Whether you should switch from an injection to a pill depends on your specific situation, including if you're staying on the same drug or a different one, and how you're doing on your current dose.

If you're staying on the same active ingredient, like switching between injectable Wegovy and the Wegovy pill, that switch is straightforward. Healthcare providers commonly switch patients using the Wegovy 2.4 mg weekly injection directly to the Wegovy 25 mg daily tablet, starting one week after their last injection. 

For people switching from other doses, your provider will decide whether to start the pill's dose-escalation schedule from the beginning or adjust based on where you are on the injection.

Switching between different drugs, say from Zepbound to Foundayo or Zepbound to the Wegovy pill, has no official conversion, since these are entirely different medications with their own active ingredients and dosing strengths. 

If you're already on an injectable GLP-1, switching to a pill doesn't necessarily mean starting over: Because your body has already adjusted to a GLP-1,  you may be able to switch without starting at the lowest dose. Your provider will tailor the approach to your situation.

Either way, this is a decision to make with your healthcare provider. Don't stop or change your dose on your own.

Oral GLP-1s for weight loss are a young category, with only two approved so far and more in development. One of them is amycretin, a once-daily pill from Novo Nordisk that combines GLP-1 with amylin, a hormone that slows gastric emptying and increases fullness.

Targeting two hormones instead of one is the same principle behind Zepbound's added strength, though Zepbound pairs GLP-1 with GIP rather than amylin.

In a phase 1 trial, oral amycretin produced greater weight loss than placebo. Novo Nordisk has since moved amycretin into phase 3 trials for weight management, which began enrolling in February 2026.

Check for free

GLP-1 pills work for weight loss, and they're a genuine option. Injections still have an edge on average, but a needle-free option that fits your routine may be easier to stick with in the long term.

• Two GLP-1 pills are FDA-approved for weight loss: oral semaglutide (Wegovy pill) and the small-molecule drug orforglipron (Foundayo). More specifically, they’re indicated for adults with obesity or a weight-related health condition, used alongside a reduced-calorie diet and increased physical activity. Two more (the Ozempic pill and Rybelsus) are approved for type 2 diabetes.

• Average weight loss with GLP-1 pills ranges from 11% to 14% over roughly 64–72 weeks, according to clinical trials. These amounts are well above what's seen with placebo.

• Injections still lead the way when it comes to weight loss results. Injectable GLP-1s edge out pills on average weight loss, though the difference between the Wegovy pill and injectable Wegovy at its original 2.4 mg dose is only about 1–2 percentage points, widening to about 5 percentage points at the 7.2 mg dose.

Talk with a Ro healthcare provider about which option fits your health history, other medications, and daily routine.